Trial Profile
An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Amgen
- 10 Oct 2020 Status changed from recruiting to completed.
- 15 Jun 2011 New trial record